Equibles does not estimate personal net worth.
Get an email with a short summary when Lineage Cell Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LCTX alertsBrian Culley is recorded as Board Member at Lineage Cell Therapeutics, Inc. (LCTX) since January 1, 2018 and CEO at Lineage Cell Therapeutics, Inc. (LCTX). The proxy statement of Lineage Cell Therapeutics, Inc. reports total compensation of $1,349,913 for Brian Culley in fiscal 2020, including a base salary of $551,900. Disclosed compensation is on record for 3 fiscal years. Brian Culley has spoken on 23 earnings calls across 1 company, most recently for Lineage Cell Therapeutics, Inc. on August 6, 2026. Lineage Cell Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lineage Cell Therapeutics, Inc. includes Brian M. Culley (CFO and Board Member), Jill A. Howe (CFO and Board Member), Alexandra Hernandez (Chief Accounting Officer) and 7 others.
“We appreciate you taking the time to join us today. As some of you know, from time to time, I like to use these calls to bring investors behind the scenes to better understand how we are advancing our programs and business.”
“We appreciate you taking the time to join us today. We have a lot of great things to cover. I'm going to try and keep it short so that we can have plenty of time for analyst questions.”
“We appreciate you taking the time to join us on the call today. We have a great call planned, highlighted by recent warrant exercises that further extend our runway, and a positive result for our initial go-no-go development milestone in our islet cell research initiative.”
“We appreciate you taking the time to join us on the call today. I'll begin with an update on our lead program, Oprygen, then review our progress against the five strategic goals which I outlined for you last quarter.”
“We appreciate you taking the time to join us on the call today. I will begin with some recent updates on the Oprogen program, then say a few words about how Oprogen's progress is driving a new strategic direction for the company.”
2018-01-01–present
Biotechnology · Healthcare
CEO, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Lineage Cell Therapeutics, Inc. (LCTX) | CEO | $551,900 | $1,349,913 |
| 2019 | Lineage Cell Therapeutics, Inc. (LCTX) | CEO | $535,800 | $772,742 |
| 2018 | Lineage Cell Therapeutics, Inc. (LCTX) | CEO | $154,923 | $2,862,707 |
